| Literature DB >> 27886127 |
Alexandra Rucavado1, Carolina A Nicolau2, Teresa Escalante3, Junho Kim4, Cristina Herrera5,6, José María Gutiérrez7, Jay W Fox8.
Abstract
Viperid snakebite envenomation is characterized by inflammatory events including increase in vascular permeability. A copious exudate is generated in tissue injected with venom, whose proteomics analysis has provided insights into the mechanisms of venom-induced tissue damage. Hereby it is reported that wound exudate itself has the ability to induce increase in vascular permeability in the skin of mice. Proteomics analysis of exudate revealed the presence of cytokines and chemokines, together with abundant damage associated molecular pattern molecules (DAMPs) resulting from both proteolysis of extracellular matrix and cellular lysis. Moreover, significant differences in the amounts of cytokines/chemokines and DAMPs were detected between exudates collected 1 h and 24 h after envenomation, thus highlighting a complex temporal dynamic in the composition of exudate. Pretreatment of mice with Eritoran, an antagonist of Toll-like receptor 4 (TLR4), significantly reduced the exudate-induced increase in vascular permeability, thus suggesting that DAMPs might be acting through this receptor. It is hypothesized that an "Envenomation-induced DAMPs cycle of tissue damage" may be operating in viperid snakebite envenomation through which venom-induced tissue damage generates a variety of DAMPs which may further expand tissue alterations.Entities:
Keywords: TLR4; damage associated molecular pattern molecules (DAMPs); exudate; increased vascular permeability; snake venom metalloproteinases (SVMPs)
Mesh:
Substances:
Year: 2016 PMID: 27886127 PMCID: PMC5198544 DOI: 10.3390/toxins8120349
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Wound exudate induces an increase in vascular permeability. Upper figures show samples of skin of mice injected intradermally with (A) wound exudate collected from mice 1 h after intramuscular injection of B. asper venom; or (B) blood plasma from untreated mice. Both groups of mice received an intravenous injection of Evans Blue solution before the injection of exudate or plasma (see Materials and Methods for details). Note the absence of Evans Blue extravasation in the control (B), whereas a clear extravasation was observed after injection of exudate (A); (C) Quantitative analysis of the increase in vascular permeability in mouse skin after injection of exudates collected 1 h and 24 h after injection of B. asper venom. In both types of exudates experiments were also performed with samples previously incubated with antivenom to neutralize the venom toxins present. One hour exudate induced a higher increase in vascular permeability than 24 h exudate. * A significant reduction in the activity by antivenom (p < 0.05) was observed only with 1 h exudate. Controls injected with mouse plasma alone or with antivenom alone did not show increase in vascular permeability.
Cytokine profile (subproteome) of wound exudates collected at 1 h and 24 h.
| Analytes (pg/mL) | Exudate 1 h | Exudate 24 h | Fold change * |
|---|---|---|---|
| CCL11 (EOTAXIN) | 220.0 | 982.4 | 4.5 |
| CSF-3 (G-CSF) | 1670.0 | >11,610.0 | >6.9 |
| CSF-2 (GM-CSF) | 21.2 | 219.0 | 10.3 |
| IFNy | 3.2 | 37.8 | 11.8 |
| IL-10 | 436.3 | 3419.0 | 7.8 |
| IL-12p40 | 10.3 | 37.5 | 3.6 |
| IL-12p70 | 5.2 | 23.8 | 4.6 |
| IL-13 | 268.4 | 1217.0 | 4.5 |
| IL-15 | 25.0 | 117.3 | 4.7 |
| IL-17 | <2.9 | 12.0 | >4.1 |
| IL-1a | 228.3 | 5952.0 | 26.1 |
| IL-1b | 8.0 | 843.1 | 105.4 |
| IL-2 | 4.8 | 9.2 | 1.9 |
| IL-3 | <2.4 | 10.2 | >4.2 |
| IL-4 | <1.4 | 4.7 | >1.9 |
| IL-5 | 15.9 | 68.1 | 4.3 |
| IL-6 | 7901.0 | >17,536.0 | >2.2 |
| IL-7 | 3.8 | 10.5 | 2.8 |
| IL-9 | 324.0 | 509.9 | 1.6 |
| CXCL10 (IP-10) | 52.6 | 2424.0 | 46.1 |
| CXCL1/GRO alpha (KC) | 4514.0 | 15,957.0 | 3.5 |
| LIF | 24.6 | 2252.0 | 91.5 |
| CXCL5 (LIX) | 1494.0 | 3817.0 | 2.5 |
| CCL2 (MCP-1) | 938.8 | >18,874.0 | >20.1 |
| CSF-1 (M-CSF) | 26.1 | 529.8 | 20.3 |
| CXCL9 (MIG) | 228.6 | 3034.0 | 13.3 |
| CCL3 (MIP-1a) | 27.9 | >14,741.0 | >528.3 |
| CCL4 (MIP-1b) | 80.7 | >14,663.0 | >181.7 |
| CXCL2 (MIP-2) | 4623.0 | 12,954.0 | 2.8 |
| CCL5 (RANTES) | 5.0 | 307.3 | 61.4 |
| TNF-a | 9.0 | 799.2 | 88.8 |
| VEGF | <1.3 | 89.3 | >68.7 |
Analyses were performed by using the Luminex quantitative analysis (see Materials and Methods for details). * Proteins showing a difference higher than 10-fold between exudates collected at the two times are highlighted.
DAMPs identified in wound exudates collected 1 and 24 h after injection of B. asper venom.
| Identified Proteins | Accession Number | Molecular Weight | Quantitative Value | Fold Change * | |
|---|---|---|---|---|---|
| 1 h | 24 h | ||||
| Hemoglobin subunit beta-2 | P02089 | 16 kDa | 745 | 1329 | 1.8 |
| Fibronectin | P11276 | 273 kDa | 274 | 290 | 1.0 |
| Fibrinogen gamma chain | Q8VCM7 | 49 kDa | 49 | 145 | 2.9 |
| Heat shock cognate 71 kDa protein | P63017 | 71 kDa | 50 | 17 | 2.9 |
| Fibrinogen beta chain | Q8K0E8 | 55 kDa | 12 | 107 | 8.9 |
| Heat shock protein HSP 90-beta | P11499 | 83 kDa | 41 | 26 | 1.6 |
| Basement membrane-specific heparan sulfate proteoglycan core protein | B1B0C7 | 469 kDa | 83 | 0 | >83 |
| Serum amyloid P-component | P12246 | 26 kDa | 27 | 65 | 2.4 |
| Histone H4 | P62806 | 11 kDa | 55 | 46 | 1.2 |
| Histone H2B type 1-M | P10854 | 14 kDa | 46 | 29 | 1.6 |
| Proteoglycan 4 | E9QQ17 | 111 kDa | 18 | 12 | 1.5 |
| Protein S100-A9 | P31725 | 13 kDa | 1 | 21 | 21 |
| Myosin light chain 1/3, skeletal muscle isoform | P05977 | 21 kDa | 10 | 59 | 5.9 |
| Myosin-9 | Q8VDD5 | 226 kDa | 64 | 30 | 2.1 |
| Serum amyloid A-4 protein | P31532 | 15 kDa | 13 | 11 | 1.1 |
| Myosin-10 | Q3UH59 | 233 kDa | 1 | 23 | 23 |
| 60 kDa heat shock protein | P63038 | 61 kDa | 18 | 0 | >18 |
| 40S ribosomal protein S19 | Q9CZX8 | 16 kDa | 0 | 34 | >34 |
| Decorin | P28654 | 40 kDa | 1 | 22 | 22 |
| Chondroitin sulfate proteoglycan 4 | Q8VHY0 | 252 kDa | 0 | 11 | >11 |
| Isoform 2 of Myosin-11 | O08638-2 | 223 kDa | 1 | 34 | 34 |
| Myosin regulatory light chain 12B | Q3THE2 | 20 kDa | 18 | 57 | 3.1 |
| Endoplasmin | P08113 | 92 kDa | 1 | 45 | 45 |
| Heat shock protein beta-1 | P14602 | 23 kDa | 37 | 45 | 1.2 |
| Calreticulin | P14211 | 48 kDa | 0 | 22 | >22 |
| Protein S100-A8 | P27005 | 10 kDa | 0 | 80 | >80 |
| Isoform Smooth muscle of Myosin | Q60605-2 | 17 kDa | 1 | 12 | 12 |
| Myosin light chain 3 | P09542 | 22 kDa | 0 | 14 | >14 |
| Heat shock protein beta-2 | Q99PR8 | 20 kDa | 27 | 0 | >27 |
| Biglycan | P28653 | 42 kDa | 0 | 22 | >22 |
| Serum amyloid A-1 protein | P05366 | 14 kDa | 0 | 16 | >16 |
* Proteins showing a difference higher than 10-fold between exudates collected at the two times are highlighted.
Figure 2Effect of Eritoran in the increase of vascular permeability induced by exudates (Ex). Exudates were collected at 1 h and 24 h from mice injected with venom. Then, a separate group of mice were pretreated with either Eritoran or saline solution. Afterwards, these mice were injected intradermally in the skin with either 1 h exudate or 24 h exudate previously incubated with antivenom to neutralize venom toxins, as described in the legend of Figure 1. The increase in vascular permeability was assessed by extravasation of Evans blue, as described in Materials and Methods. The following experimental groups were used: Ex 1h: Mice injected with 1 h exudate; Eritoran Ex 1h: Mice pretreated with Eritoran and then injected with 1 h exudate; Ex 24h: Mice injected with 24 h exudate; Eritoran Ex 24h: Mice pretreated with Eritoran and then injected with 24 h exudate. Control mice pretreated with Eritoran and then injected intradermally with either mouse plasma or antivenom did not develop any extravasation of Evans blue. * Eritoran significantly reduced the effect induced by 24 h exudate (p < 0.05) but not by 1 h exudate.
Figure 3Hypothetical summary of the proposed events occurring in tissue injected with B. asper venom. (A) Venom toxins, particularly snake venom metalloproteinases (SVMPs), PLA2s and hyaluronidases, induce direct damage to the tissue, especially acute muscle fiber necrosis and degradation of extracellular matrix components, such as those of the basement membrane of capillary vessels, and other matrix molecules, including hyaluronic acid. Acute inflammation ensues, with the release of many types of mediators that promote an increase in vascular permeability, recruitment of inflammatory cells, and pain. Such acute tissue damage is also associated with the release of multiple damage associated molecular pattern molecules (DAMPs), both intracellular and extracellular; (B) DAMPs act on a variety of cells, including endothelial cells, other resident cells, and incoming inflammatory leucocytes, to generate diverse tissue responses, such as increase in vascular permeability, and the synthesis of a variety of cytokines and chemokines, which further contribute to the inflammatory scenario in a highly complex interplay. ROS: Reactive oxygen species; LCs: leukotrienes; PGs: prostaglandins; NO: Nitric oxide.